Thomson P C, Stirling C M, Geddes C C, Morris S T, Mactier R A
Renal Unit, Glasgow Royal Infirmary, 84 Castle Street, Glasgow, UK.
QJM. 2007 Jul;100(7):415-22. doi: 10.1093/qjmed/hcm040. Epub 2007 May 25.
Bacteraemia and the development of sepsis syndrome is second only to cardiovascular disease as the leading cause of death in patients on renal replacement therapy.
To determine the contributions of laboratory and clinical variables to the risk of bacteraemia and death in haemodialysis patients.
Retrospective analysis.
We analysed all patients receiving haemodialysis in our renal unit at the beginning of January 2004 (n=263), recording clinical and laboratory variables for each patient at study entry. Bacteraemia and mortality were recorded for the subsequent 18-month period. Multivariate analysis using a Cox proportional hazards model was used to test for independent associations between variables and outcomes.
During the study period, 45 patients (17.1%) developed bacteraemia and 65 (24.7%) died. Under multivariate analysis, use of dialysis catheters at study entry was a major factor in the development of bacteraemia and death with hazard ratios (HR) of 5.4 (p<0.001) and 2.8 (p=0.012), respectively, for tunnelled central venous catheters vs. arteriovenous fistulas (AVFs) and 3.1 (p=0.01) and 3.4 (p=0.001), respectively, for non-tunnelled central venous catheters vs. AVFs. Elevated CRP at study entry was independently associated with bacteraemia (HR 1.5 per unit log-CRP, p=0.006). Low serum albumin (HR 0.92, p=0.005) was independently associated with death.
Use of synthetic vascular access catheters and heightened inflammatory state both have strong independent associations with subsequent bacteraemia and death. Bacteraemia surveillance strategies should be developed, with consideration of vascular access type and baseline inflammatory state as key components.
在接受肾脏替代治疗的患者中,菌血症和脓毒症综合征的发生是仅次于心血管疾病的第二大主要死因。
确定实验室和临床变量对血液透析患者菌血症和死亡风险的影响。
回顾性分析。
我们分析了2004年1月初在我们肾脏科接受血液透析的所有患者(n = 263),记录了每位患者在研究开始时的临床和实验室变量。记录随后18个月期间的菌血症和死亡率。使用Cox比例风险模型进行多变量分析,以检验变量与结果之间的独立关联。
在研究期间,45名患者(17.1%)发生了菌血症,65名患者(24.7%)死亡。在多变量分析中,研究开始时使用透析导管是菌血症和死亡发生的主要因素,隧道式中心静脉导管与动静脉内瘘(AVF)相比,菌血症和死亡的风险比(HR)分别为5.4(p < 0.001)和2.8(p = 0.012),非隧道式中心静脉导管与AVF相比,菌血症和死亡的风险比分别为3.1(p = 0.01)和3.4(p = 0.001)。研究开始时CRP升高与菌血症独立相关(每单位对数CRP的HR为1.5,p = 0.006)。低血清白蛋白(HR 0.92,p = 0.005)与死亡独立相关。
使用合成血管通路导管和炎症状态升高均与随后的菌血症和死亡有很强的独立关联。应制定菌血症监测策略,将血管通路类型和基线炎症状态作为关键因素加以考虑。